Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.

Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ.

ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.

2.

Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site.

Xu S, Uddin MJ, Banerjee S, Duggan K, Musee J, Kiefer JR, Ghebreselasie K, Rouzer CA, Marnett LJ.

J Biol Chem. 2019 May 31;294(22):8690-8698. doi: 10.1074/jbc.RA119.007405. Epub 2019 Apr 18.

3.

Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site.

Goodman MC, Xu S, Rouzer CA, Banerjee S, Ghebreselasie K, Migliore M, Piomelli D, Marnett LJ.

J Biol Chem. 2018 Mar 2;293(9):3028-3038. doi: 10.1074/jbc.M117.802058. Epub 2018 Jan 11.

4.

Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization.

Uddin MJ, Moore CE, Crews BC, Daniel CK, Ghebreselasie K, McIntyre JO, Marnett LJ, Jayagopal A.

J Biomed Opt. 2016 Sep 1;21(9):90503. doi: 10.1117/1.JBO.21.9.090503.

5.

Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.

Uddin MJ, Crews BC, Xu S, Ghebreselasie K, Daniel CK, Kingsley PJ, Banerjee S, Marnett LJ.

ACS Chem Biol. 2016 Nov 18;11(11):3052-3060. Epub 2016 Sep 19.

6.

Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics.

Konkle ME, Blobaum AL, Moth CW, Prusakiewicz JJ, Xu S, Ghebreselasie K, Akingbade D, Jacobs AT, Rouzer CA, Lybrand TP, Marnett LJ.

Biochemistry. 2016 Jan 19;55(2):348-59. doi: 10.1021/acs.biochem.5b01222. Epub 2015 Dec 31.

7.

nido-Dicarbaborate Induces Potent and Selective Inhibition of Cyclooxygenase-2.

Neumann W, Xu S, Sárosi MB, Scholz MS, Crews BC, Ghebreselasie K, Banerjee S, Marnett LJ, Hey-Hawkins E.

ChemMedChem. 2016 Jan 19;11(2):175-8. doi: 10.1002/cmdc.201500199. Epub 2015 Jun 18.

8.

Targeted imaging of cancer by fluorocoxib C, a near-infrared cyclooxygenase-2 probe.

Uddin MJ, Crews BC, Ghebreselasie K, Daniel CK, Kingsley PJ, Xu S, Marnett LJ.

J Biomed Opt. 2015 May;20(5):50502. doi: 10.1117/1.JBO.20.5.050502.

9.

Action at a distance: mutations of peripheral residues transform rapid reversible inhibitors to slow, tight binders of cyclooxygenase-2.

Blobaum AL, Xu S, Rowlinson SW, Duggan KC, Banerjee S, Kudalkar SN, Birmingham WR, Ghebreselasie K, Marnett LJ.

J Biol Chem. 2015 May 15;290(20):12793-803. doi: 10.1074/jbc.M114.635987. Epub 2015 Mar 30.

10.

Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.

Uddin MJ, Elleman AV, Ghebreselasie K, Daniel CK, Crews BC, Nance KD, Huda T, Marnett LJ.

ACS Med Chem Lett. 2014 Oct 12;5(11):1254-8. doi: 10.1021/ml500344j. eCollection 2014 Nov 13.

11.

Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Neumann W, Crews BC, Sárosi MB, Daniel CM, Ghebreselasie K, Scholz MS, Marnett LJ, Hey-Hawkins E.

ChemMedChem. 2015 Jan;10(1):183-92. doi: 10.1002/cmdc.201402353. Epub 2014 Oct 15.

12.

Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts.

Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ.

ACS Med Chem Lett. 2014 Jan 23;5(4):446-50. doi: 10.1021/ml400485g. eCollection 2014 Apr 10.

13.

PET radiotracer [¹⁸F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation.

Perrone MG, Malerba P, Uddin J, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A.

Eur J Med Chem. 2014 Jun 10;80:562-568. doi: 10.1016/j.ejmech.2014.04.074. Epub 2014 Apr 29.

14.

Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.

Xu S, Hermanson DJ, Banerjee S, Ghebreselasie K, Clayton GM, Garavito RM, Marnett LJ.

J Biol Chem. 2014 Mar 7;289(10):6799-808. doi: 10.1074/jbc.M113.517987. Epub 2014 Jan 14.

15.

Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents.

Uddin MJ, Crews BC, Ghebreselasie K, Marnett LJ.

Bioconjug Chem. 2013 Apr 17;24(4):712-23. doi: 10.1021/bc300693w. Epub 2013 Mar 28.

16.

Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.

Liedtke AJ, Crews BC, Daniel CM, Blobaum AL, Kingsley PJ, Ghebreselasie K, Marnett LJ.

J Med Chem. 2012 Mar 8;55(5):2287-300. doi: 10.1021/jm201528b. Epub 2012 Feb 14.

17.

Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.

Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ.

Cancer Prev Res (Phila). 2011 Oct;4(10):1536-45. doi: 10.1158/1940-6207.CAPR-11-0120. Epub 2011 Sep 7.

18.

[I]-Celecoxib Analogues as SPECT Tracers of Cyclooxygenase-2 in Inflammation.

Uddin MJ, Crews BC, Ghebreselasie K, Tantawy MN, Marnett LJ.

ACS Med Chem Lett. 2011 Feb 10;2(2):160-164. Epub 2010 Nov 12.

19.

Chemical stability of 2-arachidonylglycerol under biological conditions.

Rouzer CA, Ghebreselasie K, Marnett LJ.

Chem Phys Lipids. 2002 Oct;119(1-2):69-82.

PMID:
12270674
20.

Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity.

Kinirons MT, Lang CC, He HB, Ghebreselasie K, Shay S, Robin DW, Wood AJ.

Br J Clin Pharmacol. 1996 Jan;41(1):69-72.

Supplemental Content

Loading ...
Support Center